BRPI0608149A2 - sal de um agonista de dopamina, composição compreendendo o mesmo, uso e processo para sua preparação e composto intermediário - Google Patents

sal de um agonista de dopamina, composição compreendendo o mesmo, uso e processo para sua preparação e composto intermediário

Info

Publication number
BRPI0608149A2
BRPI0608149A2 BRPI0608149-5A BRPI0608149A BRPI0608149A2 BR PI0608149 A2 BRPI0608149 A2 BR PI0608149A2 BR PI0608149 A BRPI0608149 A BR PI0608149A BR PI0608149 A2 BRPI0608149 A2 BR PI0608149A2
Authority
BR
Brazil
Prior art keywords
salt
preparation
dopamine agonist
intermediate compound
composition
Prior art date
Application number
BRPI0608149-5A
Other languages
English (en)
Inventor
Stuart Peter Green
Olivier Alain Lazaari
Fabrice Henri Salingue
Duncan Charles Miller
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of BRPI0608149A2 publication Critical patent/BRPI0608149A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)

Abstract

SAL DE UM AGONISTA DE DOPAMINA, COMPOSIçãO COMPREENDENDO O MESMO, USO E PROCESSO PARA SUA PREPARAçãO E COMPOSTO INTERMEDIáRIO. A presente inveição refere-se a uma nova forma de sal de agonista de dopamina 5-[(2R,5 S)-5-metil-4-propilmorfoíin-2-iI]piridin-2-amina (1):Mais particularriente, esta invenção refere-se a 5-[(2R,5S)-5-metil-4-propilmorfolin-2-il]piridin-2-amina di-(1 S)-canfossulfonato (di-S-cansilato) e a processos para a preparação do mesmo, intermediários usados na preparação do mesmo, composições que contêm o mesmo e aos usos desse sal.
BRPI0608149-5A 2005-02-07 2006-01-26 sal de um agonista de dopamina, composição compreendendo o mesmo, uso e processo para sua preparação e composto intermediário BRPI0608149A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502509.3A GB0502509D0 (en) 2005-02-07 2005-02-07 Novel salt form of a dopamine agonist
PCT/IB2006/000222 WO2006082511A1 (en) 2005-02-07 2006-01-26 Novel salt form of a dopamine agonist

Publications (1)

Publication Number Publication Date
BRPI0608149A2 true BRPI0608149A2 (pt) 2009-11-10

Family

ID=34355919

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608149-5A BRPI0608149A2 (pt) 2005-02-07 2006-01-26 sal de um agonista de dopamina, composição compreendendo o mesmo, uso e processo para sua preparação e composto intermediário

Country Status (26)

Country Link
US (1) US7498329B2 (pt)
EP (1) EP1848709B1 (pt)
JP (1) JP4157158B2 (pt)
KR (1) KR100997033B1 (pt)
CN (1) CN101115737B (pt)
AR (1) AR053122A1 (pt)
AT (1) ATE509924T1 (pt)
AU (1) AU2006211033A1 (pt)
BR (1) BRPI0608149A2 (pt)
CA (1) CA2595815C (pt)
DO (1) DOP2006000030A (pt)
ES (1) ES2364345T3 (pt)
GB (1) GB0502509D0 (pt)
GT (1) GT200600040A (pt)
HN (1) HN2006004827A (pt)
IL (1) IL184395A0 (pt)
MX (1) MX2007008462A (pt)
NL (1) NL1031087C2 (pt)
NZ (1) NZ556292A (pt)
PA (1) PA8662001A1 (pt)
PE (1) PE20061034A1 (pt)
RU (1) RU2393153C2 (pt)
TW (1) TWI314930B (pt)
UY (1) UY29365A1 (pt)
WO (1) WO2006082511A1 (pt)
ZA (1) ZA200605491B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8522799B2 (en) * 2005-12-30 2013-09-03 Lam Research Corporation Apparatus and system for cleaning a substrate
KR100913791B1 (ko) * 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
ES2607806T5 (es) 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
CA2964103C (en) 2014-10-31 2022-08-30 Indivior Uk Limited Dopamine d3 receptor antagonist compounds
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
RU2622018C1 (ru) * 2016-06-16 2017-06-08 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Быстро растворяющаяся трансбуккальная плёнка для лечения депрессивных расстройств, тревоги и расстройств адаптации
WO2020210785A1 (en) 2019-04-12 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2168509C1 (ru) * 1999-10-19 2001-06-10 Институт нефтехимии и катализа АН РБ и УНЦ РАН 2-(n-морфолил)-4-метилпиридин в качестве ингибитора кислотной коррозии стали
EA009589B1 (ru) * 2002-12-10 2008-02-28 Пфайзер Инк. Производные морфолина для применения в качестве агонистов допамина при лечении половой дисфункции
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP4198183B2 (ja) * 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体

Also Published As

Publication number Publication date
KR20070094647A (ko) 2007-09-20
UY29365A1 (es) 2006-10-02
RU2393153C2 (ru) 2010-06-27
ATE509924T1 (de) 2011-06-15
TW200639164A (en) 2006-11-16
ZA200605491B (en) 2008-09-25
HN2006004827A (es) 2010-06-09
CN101115737A (zh) 2008-01-30
PE20061034A1 (es) 2006-10-19
EP1848709A1 (en) 2007-10-31
US20060183740A1 (en) 2006-08-17
WO2006082511A1 (en) 2006-08-10
AU2006211033A1 (en) 2006-08-10
JP4157158B2 (ja) 2008-09-24
TWI314930B (en) 2009-09-21
CN101115737B (zh) 2010-12-01
NL1031087C2 (nl) 2007-01-19
CA2595815A1 (en) 2006-08-10
NL1031087A1 (nl) 2006-08-08
KR100997033B1 (ko) 2010-11-26
JP2008529997A (ja) 2008-08-07
NZ556292A (en) 2010-10-29
AR053122A1 (es) 2007-04-25
CA2595815C (en) 2010-07-27
MX2007008462A (es) 2007-07-25
PA8662001A1 (es) 2006-09-08
ES2364345T3 (es) 2011-08-31
GB0502509D0 (en) 2005-03-16
DOP2006000030A (es) 2006-08-15
GT200600040A (es) 2007-01-12
IL184395A0 (en) 2007-10-31
EP1848709B1 (en) 2011-05-18
RU2007130150A (ru) 2009-03-20
US7498329B2 (en) 2009-03-03

Similar Documents

Publication Publication Date Title
BRPI0606318A2 (pt) composto, composição, e, uso de um composto
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0717970B8 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
BRPI0516105A (pt) composições de fator de crescimento derivado de plaqueta e métodos de uso destas
BRPI0500393B8 (pt) forma cristalina ii de agomelatina e sua composição farmacêutica
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
BR112015009048A2 (pt) composições pesticidas agrícolas
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
BRPI0608097A2 (pt) composto ou enanciÈmeros, diastereÈmeros, sais, solvatos e n-óxidos do mesmo, composição farmacêutica, e,uso de uma quantidade eficaz de um composto
CL2007001759A1 (es) Compuesto metformina r-(+) lipoato; mezcla que comprende metformina y acido r-(+) lipoico; composicion farmaceutica que comprende el compuesto; metodo para preparar el compuesto; kit; y uso para tratar la diabetes.
BR112013005138B8 (pt) uso de uma composição
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
BRPI0911681B8 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
CL2008001302A1 (es) Compuestos derivados de tetramatos sustituidos con 3-(2-alcoxifenilo); su proceso de preparacion de los mismos; agente para combatir plagas animales y/o vegetacion indeseada; procedimiento para su preparacion; uso de dichos compuestos; composicion que comprende a dichos compuestos; y procedimiento para combatir vegetacion indeseada.
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
WO2008112164A3 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BR112018011859A2 (pt) uso de composições tendo um conteúdo de 3,3´-metilenobis(2-metiloxazolidina) na remoção de compostos de enxofre a partir de correntes de processo
ECSP099071A (es) Agonistas de ep2
HN2008000088A (es) Heterociclicos de 1,4-dihidropiridina- fusionada, procesos para preparar los mismos, su uso y las composiciones que los contienen.
UY29157A1 (es) Composiciones de amitraz
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2161 DE 05/06/2012.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013.